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There is a high and rising prevalence of prostate cancer (PRCA) within the male population of the United Kingdom. Although the
relative risk of PRCA is higher in male BRCA2 and BRCA1 mutation carriers, the histological characteristics of this malignancy in these
groups have not been clearly defined. We present the histopathological findings in the first UK series of BRCA1 and BRCA2 mutation
carriers with PRCA. The archived histopathological tissue sections of 20 BRCA1/2 mutation carriers with PRCA were collected from
histopathology laboratories in England, Ireland and Scotland. The cases were matched to a control group by age, stage and serum
PSA level of PRCA cases diagnosed in the general population. Following histopathological evaluation and re-grading according to
current conventional criteria, Gleason scores of PRCA developed by BRCA1/2 mutation carriers were identified to be significantly
higher (Gleason scores 8, 9 or 10, P¼0.012) than those in the control group. Since BRCA1/2 mutation carrier status is associated
with more aggressive disease, it is a prognostic factor for PRCA outcome. Targeting screening to this population may detect disease
at an earlier clinical stage which may therefore be beneficial.
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Prostate cancer (PRCA) is the most commonly diagnosed
malignancy in men in the United Kingdom. It is thought to be
composed of aggressive and indolent varieties. Indolent PRCA may
exist for many years without causing symptoms or shortening life
expectancy. Aggressive PRCA may cause symptoms difficult to
palliate with conventional treatments and is likely to shorten life
expectancy. Distinguishing which men are at risk of which types
of disease could have far-reaching consequences not only in the
treatment and follow-up of patients but also in the surveillance of
groups at risk of aggressive PRCA.
The morphology of breast cancer found in female BRCA1 and
BRCA2 germline mutation carriers has been studied extensively. The
histopathological features of breast tumours from patients with
BRCA1 and BRCA2 mutations differ from each other and from
sporadic breast cancers (Lakhani et al, 1998). BRCA1 and BRCA2
breast cancers are of higher grade (Lakhani, 2001). BRCA1-
associated tumours are more likely to be oestrogen, progesterone
receptor and Her2 receptor negative, express TP53 protein, and
demonstrate medullary/atypical medullary morphology. Lakhani
(2001) predicts that a woman diagnosed with high-grade, oestrogen
receptor-negative breast cancer before the age of 30 years has a 40–
45% chance of harbouring a BRCA1 mutation, compared with a 4–
5% chance if these parameters are not met (Lakhani, 2001). Many of
the features identified in breast cancer in women who are BRCA1
mutation carriers are associated with a poor prognosis. If similar
data were available for men with PRCA who are carriers of these
mutations, weighing up the options for radical treatment or active
surveillance could be simplified with this added information.
Despite studies on the incidence of PRCA in male BRCA1 and
BRCA2 mutation carriers, there are sparse data recording the
histopathology of the disease they develop. The largest and most
recent study reports a series of 30 male BRCA2 (999del5) Icelandic
founder mutation carriers. The mutation carriers had PRCA with a
significantly higher Gleason score, lower mean age of diagnosis,
more advanced stage and shorter median survival than a control
group (Tryggvado ´ttir et al, 2007). Before this, the largest series was
reported by Giusti et al (2003).Twenty-nine carriers of Ashkenazi
Jewish (AJ) founder BRCA1/2 mutations who had developed PRCA
were compared with non-carriers with PRCA. No difference was
seen in Gleason pattern, incidence of prostatic intraepithelial
neoplasia (PIN) or atypical adenomatous hyperplasia (Giusti et al,
2003). In another study, Hubert et al (1999) compared two groups
each of 87 Israeli men: one group diagnosed with PRCA and the
other a control group. The number of AJ founder mutations was
found to be the same in each group. The three mutation carriers in
the PRCA group were found to have an average Gleason score
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sabove 8, compared with a Gleason score of 5.9 for non-carriers
with PRCA (Hubert et al, 1999). The serum PSA level was also
higher than that in non-carriers. Gro ¨nberg et al (2001) reported a
family of five male 999del5 BRCA2 mutation carriers from Sweden,
who developed poorly differentiated PRCA at an early age of onset
with a shortened life expectancy (Gro ¨nberg et al, 2001). A recent
PRCA screening study enrolled 19 male BRCA1/2 mutation carriers
(12 BRCA1 and 7 BRCA2) and an age-matched control group of
men with at least one first-degree relative with PRCA. Annual
serum PSA (threshold for prostate biopsy 4ngml
 1) and digital
rectal examination were undertaken. The two mutation carriers
with PRCA were noted to have Gleason scores of 6 and 9 compared
with the single subject from the control group who had a Gleason
score of 6 (Horsburgh et al, 2005).
When applied correctly, the Gleason scoring system is the most
robust and reproducible method currently available for grading
the morphological appearances of PRCA (Gleason et al, 1966). The
criteria and their application are well documented but often
require adjustment and standardisation if these criteria have not
been applied by an expert urological pathologist (Foster, 1991;
Deshmukh and Foster, 1998; Epstein et al, 2005; Berney et al,
2007a,b). Currently, the Gleason score is used as a prognostic
indicator for individual PRCAs in the general population. But the
features of PRCA developing in men who harbour a BRCA1 or
BRCA2 mutation are not well established. This paper reports the
histopathological features of the first UK series of male BRCA1 and
BRCA2 mutation carriers with PRCA.
MATERIALS AND METHODS
Prostate cancer tissue was collected from cases and controls. A
total of 20 cases with BRCA1 or BRCA2 mutations was collected
from throughout the United Kingdom and Ireland. These were
identified from four sources described below: the EMBRACE
(Epidemiological Study of Familial Breast Cancer) study, the
IMPACT (Identification of Men with a Genetic Predisposition to
Prostate Cancer: Targeted Screening in BRCA1/2 Mutation Carriers
and Controls) study, a Cancer Genetics outpatient clinic and a
series of young onset PRCAs.
Men with PRCA enrolled in the EMBRACE study had consented
to the use of their prostate tissue samples for further research.
The hospitals where these men had undergone prostate biopsy,
prostatectomy or transurethral resection of the prostate (TURP)
sent blocks/slides containing prostate tissue to AM. This material
was coded anonymously with a unique study number. Where
original haematoxylin and eosin slides were not sent, new ones
were cut at The Institute of Cancer Research from the blocks
provided. Twelve slides were obtained in this manner from
England, Ireland and Scotland.
IMPACT is an international screening study for men unaffected by
cancer with a known BRCA1 or BRCA2 mutation (and therefore
believed to be at increased risk of developing PRCA). One man who
was diagnosed with PRCA was recruited from the IMPACT study.
One individual was recruited from the Cancer Genetics out-
patient clinic in the Royal Marsden NHS Foundation Trust (RMH).
Six further slides were obtained from The Institute of Cancer
Research. A series of 263 men who had PRCA diagnosed under the
age of 55 years had previously undergone retrospective BRCA2
mutation analysis using conformational sensitive capillary electro-
phoresis, which was then confirmed by sequencing. Prostate tissues
from the six men found to have deleterious BRCA2 mutations were
incorporated into the current study (Edwards et al, 2003).
Controls were obtained from a data set of 4893 men with a
diagnosis of PRCA who had been treated at the RMH between 1985
and 2006. One control was obtained from the Royal Liverpool
University Hospital. Men were matched for age (±5 years)
wherever possible. The age range was greater than this in four
cases (with differences of 7, 9, 9 and 10 years), where it proved
difficult to obtain better-matched controls. PSA and disease stage
were matched as closely as possible when this information was
available from the medical notes. Where PSA or stage was not
available, the controls were chosen to have a higher PSA and/or a
more advanced stage (Tables 2 and 4). The controls comprised 17
needle biopsies, 2 TURPs and 1 wedge biopsy. Two men from the
control group had been tested for and did not harbour any BRCA2
mutations.
Histopathological slides were reviewed by specialist urological
pathologists. Seventeen of the control group PRCA slides and all
20 of the BRCA1 and BRCA2 mutation carriers’ PRCA slides
were reviewed by a single specialist histopathologist from a tertiary
referral centre (CSF). Three of the remaining control group slides
were reviewed by one other single, specialist histopathologist, CJ
from RMH, a specialist tertiary referral centre. The histopatho-
logists each cross-checked the reporting of a subset of the other’s
tissue sections to ensure consistency.
Throughout this study, we have employed only the original
grading system, as described by Gleason (1966) and explained by
Professor Deshmukh and Foster (1998) (Gleason, 1966; Deshmukh
and Foster, 1998). A poorly differentiated tumour was defined as a
Gleason pattern greater than 7, that is, combined Gleason score of
8, 9 or 10. Perineural invasion (PNI) and lymphovascular invasion
(LVI) were also recorded in each case. The handling of tertiary
grades is of practical importance only with respect to grade 7 cancers.
The convention defined in the consensus meeting of the International
Society of Urological Pathologists, 2005, in which CSF participated,
was followed. In this recommendation, PRCAs with a Gleason score
of 3þ4o r4þ3 together with a tertiary pattern 5 have their PRCA
classified as Gleason score 8 or 9, respectively.
Statistical methods
BRCA1/2 mutation carriers were matched with controls for age,
PSA and stage of disease to minimise the effect of these factors on
the Gleason score comparison. McNemar’s test was used to
compare the Gleason score (p7 vs 47) and presence or absence of
PNI and LVI between cases and controls (see Tables 6–11). This
test looks for differences between the row and column marginal
frequencies. It is based on the idea that if there are really no
differences in the Gleason scores of BRCA1/2 mutation carriers and
non-carriers, then any differences in our sample must have arisen
by chance, and are equally likely to occur in favour of the cases
than of the controls. Therefore, if there were really no differences,
we would expect the number of cases with a low Gleason score who
are matched to a control with a high Gleason score (n¼1i n
Table 6) to be roughly equal to the number of cases with a high
Gleason score who are matched to a control with a low Gleason
score (n¼10 in Table 6).
RESULTS
Tables 1–5 show the characteristics of the patients. The staging of
the disease has been corrected to the TNM classification of 2002.
Patients’ characteristics
There was a total of 20 cases and 20 controls (4 BRCA1 and 16
BRCA2) (Tables 1 and 3). For the majority of matched cases
and controls, where the cases presented with symptomatic or
asymptomatic (screen-detected) disease, the controls were
matched in the same way. If it was not possible to match for
presentation (screen-detected or symptomatic), the controls were
matched to present with symptoms for comparison with cases that
presented as a result of screening. This was not possible for three
BRCA2 cases and one BRCA1 case; however, where a control either
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shad unknown presentation or screen-detected disease, the cases
that were matched presented with symptomatic disease (Tables 2
and 4).
Of the BRCA2 mutation carriers, nine presented with symptoms,
which preceded the diagnosis of PRCA, four men had screen-
detected disease and this information was missing for three men.
Nine of the control group presented with symptoms, four were
screened and three had an unknown presentation.
Three BRCA1 mutation carriers had screen-detected disease.
Comparison of BRCA1 and BRCA2 mutation carriers with
PRCA and controls
There was a significant difference in the Gleason score between
patients with BRCA1 and BRCA2 mutations who had developed
PRCA and the controls (Table 6, McNemar’s test, P¼0.012). There
was no difference in PNI or LVI between the two groups (Tables 7
and 8, McNemar’s test, P¼1.00 in both cases).
BRCA2 patients alone
When the group of BRCA1/2 mutation carriers was divided, the
statistically significant difference in Gleason scores between
BRCA2 mutation carriers and controls was maintained (Table 9,
P¼0.016 using McNemar’s test). There was again no difference in
PNI or LVI in the two groups (Tables 10 and 11, McNemar’s test,
P¼1.00 in both cases). The BRCA1 mutation carrier group was too
small to show statistically significant results.
DISCUSSION
We have reported the histopathology found in the first UK series
of male BRCA2 and BRCA1 mutation carriers with PRCA. The men
who carry the mutations have a diverse heritage (consistent with
our population); as such our series is not confined to a few founder
mutations. The number of PRCAs with Gleason score 8, 9 or 10 is
significantly greater in the BRCA1/2 mutation carrier group than
that in the control group (P¼0.012). This difference is also seen
between the BRCA2 mutation carriers alone and the matched
control group (P¼0.016). These findings would support studies
that suggest that male BRCA2 mutation carriers who develop
PRCA may have a shorter disease-specific life expectancy than men
with PRCA in the general population (Sigurdsson et al, 1997;
Edwards et al, 1998, 2005; Tryggvado ´ttir et al, 2007).
The Breast Cancer Linkage Consortium has conducted a large
prospective cohort study. It demonstrated that BRCA2 mutation
carriers have a relative risk (RR) of PRCA of 4.65 rising to 7.33
below the age of 65 years and BRCA1 mutation carriers have an RR
of PRCA of 1.82 under the age of 65 years (BCLC, 1999; Thompson
et al, 2002). Similar data have been recorded in the AJ population
Table 1 BRCA2 carrier mutation status
IM01 6819delTG
IM04 6174delT
IM05 5910C4G (Y1894X)
IM06 7771insA
IM07 6503delTT
IM09 3386T4G
IM11 6503delTT
IM12 3386T4G
IM13 7084delAAAAG*
IM14 2558insA
IM15 7772insA*
IM16 6710delACAA
IM18 Nucleotide variation 2, intron G4C 1 BP BEF splice site
IM19 5531delTT
IM21 8395G4C (D2723H)
IM22 8205-1G4C
These mutations are described as pathogenic in the Breast Cancer Mutation
Database (BIC; http://research.nhgri.nih.gov/bic/) with the exception of those marked
* that are described as pathogenic by Edwards et al (2003).
Table 2 Age (years), PSA (ngml
 1), TNM stage, method of detection and year of presentation for BRCA2 mutation carriers
Age (years) PSA (ngml
 1) TNM stage Detection Year of presentation
Case Control Case Control Case Control Case Control Case Control
57 59 16.6 7.05 M1 T3aN1M1c Symptomatic Symptomatic 1998 1999
58 61 4.7 3.4 M1 T2aNXM1 Symptomatic Symptomatic 2004 1998
67 67 107 400 Unknown T3NxM1 Unknown Symptomatic 2004 2004
54 52 4.6 6.0 Clinical T1c, pT2c Clinical T1 Screened Screened,
BRCA2 negative
2000 1996
46 47 151 127 Negative bone scan,
clinically localised
Clinical T3N1 Screened Symptomatic 1998 2001
46 53 4.5 17 M1–ext. iliac LN Clinical T3NxMx Screened Symptomatic,
BRCA2 negative
2004 1995
57 56 4.7 3.5 pT2cN0 Clinical T2a Symptomatic Screened 2004 2003
46 55 Predated PSA 203 M1 bone metastases Clinical T3N0M1 Symptomatic Symptomatic 1971 2003
47 52 32 49.5 T3N0M1 T3N1M1 Symptomatic Unknown 1995 Unknown
48 57 o1 4.6 T2N0M0 T1c Symptomatic Screened 1992 2003
53 58 227 200 T3aN0M0 T2NxM1 Symptomatic Symptomatic 1994 1996
52 49 Unknown 141 Unknown T4NxM1 Symptomatic Symptomatic 1990 1990
44 39 139 48.5 M1 T4N1M1 Symptomatic Symptomatic 2000 2005
56 53 Unknown 4100 T3N0M0 T3NxM1 Unknown Symptomatic 1992 1995
45 50 4.1 5.6 Organ confined T2, organ confined Screened Screened 1997 2002
57 67 685 666 Unstaged Unstaged Unknown Unknown 1999 2006
Table 3 BRCA1 carrier mutation status
IM02 3875delGTCT
IM03 1294del40
IM08 185delAG
IM10 185delAG
These mutations are described as pathogenic in the Breast Cancer Mutation
Database (BIC; http://research.nhgri.nih.gov/bic/).
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although smaller clinical studies have generally not demonstrated
an increased frequency of founder BRCA1/2 mutations among
Jewish men with PRCA (Lehrer et al, 1998; Hubert et al, 1999;
Nastiuk et al, 1999; Vazina et al, 2000).
In the current data set, six men were identified from a previous
study conducted at The Institute of Cancer Research, as described
in the Materials and Methods section. As these men were selected
for mutation analysis following the diagnosis of young onset
PRCA, this data set is skewed for young age and so the controls
have been matched for age. The median age of PRCA diagnosis in
the BRCA2 mutation carriers is 52.5 years and in the matched
control group it is 55.5 years. The difference between these two age
groups is not significant, but the age of onset in these groups is
considerably less than the average age of onset of PRCA in the UK
general population (75 years) (www.statistics.gov.uk). It is possible
that PRCA in a young age group may show a different
histopathology to that in an older age group. However, the
controls were matched for age and were found to have a
significantly lower Gleason score. Prostate cancer incidence has
been shown to be higher in BRCA1 and BRCA2 mutation carriers
under the age of 65 years (BCLC, 1999; Thompson et al, 2002). If
these carriers do develop more aggressive disease at a younger age
than the general population, then screening them for PRCA may be
a prudent use of resources.
Matching the cases to the control group was not always
straightforward. Prostate cancer dedifferentiates over time (Draisma
et al, 2006). Therefore, it can be difficult to match men who may
Table 4 Age, PSA, TNM stage, method of detection and year of presentation for BRCA1 mutation carriers
Age (years) PSA (ngml
 1) TNM stage Detection Year of presentation
Case Control Case Control Case Control Case Control Case Control
62 64 11.6 13 P T3N0M0 T3aN0M0 Screened Symptomatic 1998 1995
69 68 6.5 6.7 Clinical T3a T3a Screened Symptomatic 2000 1996
70 74 13.4 8.3 Clinical T3N0M0 T3 Symptomatic Screened 2003 2003
48 50 3.8 0.6 Clinical T1c T3bN0M0 Screened Symptomatic 2006 1997
Table 5 Age and PSA data available
Median age (cases) Median age (controls) Significance
BRCA2 series 52.5 (44–67) 55.5 (39–67) Wilcoxon signed-ranks, P¼0.056
BRCA1 series 65.5 (48–70) 66.0 (50–74) Wilcoxon signed-ranks, P¼0.141
Median PSA (cases) Median PSA (controls) Significance
BRCA2 series 24.3 (4.1–685.0) 32.8 (3.4–666.0) Wilcoxon signed ranks, P¼0.583
BRCA1 series 9.1 (3.8–13.4) 7.5 (0.6–13.0) Wilcoxon signed ranks, P¼0.465
Combined BRCA1+2 12.5 (3.8–685.0) 10.7 (0.6–666.0) Wilcoxon signed ranks, P¼0.438
Table 6 Gleason score of BRCA1/2 mutation carriers and their matched
controls
Controls
Gleason p7 Gleason 47 Total
BRCA1/2 mutation carriers
Gleason p72 1 3
Gleason 471 0 7 1 7
Total 12 8 20
Table 7 PNI status of BRCA1/2 mutation carriers and their matched
controls
Control PNI
No Yes Total
BRCA1/2 cases PNI
No 5 6 11
Yes 6 2 8
Total 11 8 19
a
PNI¼perineural invasion.
aPNI was reliably commented upon in 19 of the cases.
Table 8 LVI status of BRCA1/2 mutation carriers and their matched
controls
Control LVI
No Yes Total
BRCA1/2 cases LVI
No 5 7 12
Yes 6 1 7
Total 11 8 19
a
LVI¼lymphovascular invasion.
aLVI was reliably commented upon in 19 of the cases.
Table 9 Gleason score of BRCA2 mutation carriers and their matched
controls
Controls
Gleason p7 Gleason 47 Total
Cases
Gleason p72 0 2
Gleason 477 7 1 4
Total 9 7 16
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sor may not have had the disease in situ for differing lengths of
time. To minimise such lead-time bias, the men in the control
group were matched for PSA and stage of disease. This produced
complications, as adequate data were not always recorded in the
patients’ medical notes. In cases where relevant data were found to
be missing, the controls were chosen with advanced stage and with
a serum PSA level higher than 100ngml
 1. This was done in order
to bias the control group towards more advanced disease and
therefore with potential for dedifferentiation to a more aggressive
Gleason pattern. This means that the effect that we have reported
in BRCA1/2 mutation carriers is probably greater in reality.
Similarly, it could be argued that men who present with
symptomatic disease could have a more advanced natural history
than those men who present with screen-detected disease (Draisma
et al, 2006). In this series of men, the controls have been carefully
chosen so that they have presented with symptoms more often
than the BRCA1/2 mutation carrier group. In the BRCA2 series, the
control group only presented with screen-detected disease in four
men, whereas the BRCA1 mutation carrier cases presented with
symptomatic disease once.
A more difficult variable for which to correct is the fact that this
series of cases and controls uses data from a variety of sources,
including prostate biopsies, TURPs and prostatectomies for
comparison. Also, the patients in this series had sextant biopsies
(Hodge et al, 1989). Reports have suggested that needle biopsy and
radical prostatectomy Gleason scores only match in 45% of cases
(Bostwick, 1994; Levine et al, 1998; King et al, 2004). This is likely
to result from intraobserver and interobserver variability in
Gleason grading and sampling error in taking the biopsy. Ozdamar
et al (1996) showed that grading error was greatest with well-
differentiated (Gleason scores 2–4) tumours. In these cases, the
accuracy was only 15% with needle biopsy (Ozdamar et al, 1996).
Of patients with Gleason scores 5–7 on needle biopsy, 97% were
graded correctly. All those with Gleason scores 8–10 on needle
biopsy were graded correctly. Deshmukh and Foster (1998) argue
that some pathologists do not identify milder forms of grade 3
PRCA and label it instead as grade 2. In this study, no PRCAs were
found to have a Gleason score less than 6.
There is also discordance in the reporting of Gleason scores
among pathologists (Allsbrook et al, 2001a). This is, however,
significantly less between specialist urological pathologists
(Allsbrook et al, 2001b). Both CJ and CSF are specialist urological
pathologists. Recently, these criteria have been used to assess a
large number of PRCAs in the United Kingdom and to resolve
discrepancies (Berney et al, 2007a,b). Risk of interobserver
variability was further minimised in this study by having CJ
review a subset of the cases and controls; there was no discordance
between the two histopathologists.
Of the 16 controls for the BRCA2 series, 14 had not been tested
for a BRCA2 mutation. Edwards et al (2003) found that the
incidence of BRCA2 mutation in early-onset PRCA sufferers
(under the age of 55 years) could be as high as 3.0% (Edwards et al,
2003). The average age of our control group was 55.5 years, so we
would expect that at most one of these men could have harboured
a BRCA2 mutation.
In conclusion, this data set is the first UK series of male BRCA1
and BRCA2 mutation carriers with PRCA. These mutation carriers
have a significantly higher Gleason score than the non-carriers
with PRCA. It would follow that the BRCA1 and BRCA2 mutations
are therefore prognostic markers for aggressive PRCA. If screening
for PRCA using serum PSA detects malignant disease at an earlier
stage, this may have the potential to reduce mortality from a
histologically aggressive disease in this population. These data
would support screening male BRCA1 and BRCA2 mutation
carriers for PRCA. The IMPACT study is currently recruiting
nationally within the United Kingdom and internationally in
Australia and Norway. IMPACT will investigate whether targeted
PSA screening detects PRCA in this subgroup of high-risk men.
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